Trump Tariffs Threaten MedTech: 3 Stocks to Mitigate Risks
Three companies that are better positioned to withstand Trump's tariff challenges are ResMed, Hims & Hers Health and Medtronic.
Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature
I anticipate the FDA will soon declare the semaglutide shortage resolved, potentially slowing Hims' revenue growth rate due to compounding restrictions. I foresee explosive revenue growth post-FDA ...
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $29.72, signifying a -0.3% move from its prior day's close.
Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Hims & Hers capitalizes on telehealth growth in hair, mental, sexual health, and weight loss. Yet, limited product differentiation, reliance on branding, and FDA risks weaken its long-term moat. Fo...
Hims & Hers donates $1 million to Trump's inauguration fund
Hims & Hers Health has donated $1 million to President-elect Donald Trump's inauguration fund, CNBC confirmed Tuesday. The company is the latest in a string of tech organizations that have tried to...
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $26.90, moving +1.01% from the previous trading session.
Is Hims & Hers Health a Millionaire Maker?
Hot telehealth stock Hims & Hers Health (HIMS -3.93%) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Will the falling Hims & Hers stock price recover in 2025?
Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped by almost 200% this year, while other companies in the industry like CVS ...
Hims & Hers Stock: Growth, Noise, and Where to Focus Now
Hims & Hers Health (HIMS -7.67%) stock is on a downward trend on both macro trends and news about GLP-1s. But this is still a growth stock investors should watch, which Travis Hoium explains in thi...
Hims and Hers Health Stock Testing Key Trendline
Hims & Hers Health Inc (NYSE:HIMS) stock is sitting out the broad market rally today, last seen down 8.4% to trade at $26.15.
Hims & Hers: Look At What Matters Most
Hims & Hers Health, Inc. has shown significant improvement in key unit economics, positioning it among top-tier SaaS companies in terms of scalability and growth potential. The company reported ste...
Options Action: Bearish bets on Hims
Mike Khouw joins 'Fast Money' to talk the options trade around Hims.
2 Telehealth Stocks That Could Gain from Trump's New FDA Pick
The Trump administration has nominated Dr. Marty Makary for the role of the United States Federal Drug Administration (FDA) commissioner. Dr. Makary is the Chief of Islet Transplant Surgery at John...
Him & Hers Health Stock Doubled Options Bulls' Money
Schaeffer's Weekend Trader subscribers scored a big win just in time for Thanksgiving.
Related Companies